CardiAMP Cell Therapy Clinical Trials

BCDA-01: CardiAMP Heart Failure Trial

About 5.7 million Americans are living with heart failure today, with about half a million more diagnosed each year. The CardiAMP Heart Failure Trial is studying an investigational stem cell-based therapy for heart failure that develops after a heart attack. The therapy takes a personalized and minimally-invasive approach to the use
of a patient’s own cells in the treatment of ischemic heart failure, and is designed to stimulate the body’s natural healing response.

The CardiAMP heart failure study is enrolling up to 260 patients at 40 medical centers throughout the United States. The study participants will be randomly placed into one of two groups, a treatment and a sham control group. Neither the patient nor the researcher will know who will be receiving the CardiAMP cell therapy and
who will be receiving the sham treatment. Both groups will be closely monitored throughout the study by a team of physicians and continue to be treated with standard of care medical treatments. 

Watch the CardiAMP Cell Therapy for Heart Failure Trial animation to learn more



Listen to Tim's and Michele's Stories

 



Learn about the CardiAMP Heart Failure Trial from our investigators








CLICK HERE TO FIND OUT IF YOU OR A LOVED ONE QUALIFIES TO PARTICIPATE IN THE CARDIAMP HEART FAILURE TRIAL

To learn more about this study, visit www.clinicaltrials.gov/ct2/show/NCT02438306

BCDA-02: CardiAMP Chronic Myocardial Ischemia Trial

It is estimated that between 600,000 to 1.8 million patients suffer from refractory angina, with approximately 75,000 new cases diagnosed each year. Refractory Angina is a chronic condition,  in the setting of coronary artery disease, that  is characterized by significant debilitating chest pain that greatly reduces quality of life.

The CardiAMP Chronic Myocardial Ischemia Trial will study an investigational stem cell-based therapy that takes a personalized and minimally-invasive approach to the use of a patient’s own cells in the treatment of chronic myocardial ischemia. Similar to BCDA-01: CardiAMP Heart Failure Trial, the therapy is designed to stimulate the body’s natural healing response.

The CardiAMP Chronic Myocardial Ischemia study will enroll up to 343 patients at 40 medical centers throughout the United States. The study participants will be randomly placed into one of two groups, a treatment and a sham control group. Neither the patient nor the researcher will know who will be receiving the CardiAMP cell therapy and
who will be receiving the sham treatment. Both groups will be closely monitored throughout the study by a team of physicians and continue to be treated with standard of care medical treatments. 

To learn more about this study, visit www.clinicaltrials.gov/ct2/show/NCT03455725

News


Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.